The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Ontario: Provincial funding for hepatitis C drugs a game changer, health professionals say

Changes spurred by development of minimally invasive drugs with extremely high cure rates. Health professionals are voicing excitement about new changes regarding the availability of hepatitis C treatment under Ontario's Drug Benefit program. The Ontario government says it will cover the cost of medication for all hepatitis C patients, regardless of the severity of the disease, a move that's being touted as a game-changing decision by health professionals

Hep C Screening Urged For Boomers, Drug Users, And Immigrants

Dr Paul Marotta, the director of liver transplantation at London Health Sciences Centre, says by eliminating barriers to access treatment, Ontario stands to save billions of dollars in its healthcare system. “It’s all covered,” he says. “From the public plan, it’s covered 100%. There’s a slight little co-pay, but really that’s a trivial amount and most of the time we find mechanisms to have that covered as well.” About 1% of the population or about 110

The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan

Gilead applauds Ontario's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Ontario's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available under the Ontario Drug Benefit Program The removal of the fibrosis level criterion for access furthers C...

The Week in Review: February 16 – February 23, 2018

Friday, February 23, 2018 News Recap: Way to Go, Ontario! Ontario removes fibrosis requirement for HCV treatment effective Feb 28th.  Action Hepatitis Canada has just shared some great news: Ontario has announced today that effective February 28, 2018, the fibrosis requirement for hepatitis C treatment will be removed! Finally, diagnosis of chronic hepatitis C and genotyping is all that will be required in Ontario to access treatment. This announcem...

Ontario removes fibrosis requirement for HCV treatment effective Feb 28th.

Action Hepatitis Canada is pleased to share some great news: Ontario has announced today that effective February 28, 2018, the fibrosis requirement for hepatitis C treatment will be removed! Finally, diagnosis of chronic hepatitis C and genotyping is all that will be required in Ontario to access treatment. This announcement comes almost one year since the pCPA negotiations which lowered hepatitis C treatment prices to the provinces and territories, ...

The Week in Review: January 19 – January 26, 2018

Friday, January 26, 2018 News Recap: Research and Discoveries: Growing Evidence Shows Hepatitis C Intersects With Other Diseases. As many as three-quarters of individuals with hepatitis C virus (HCV) experience disorders related to the virus beyond the impact on their livers, the National Viral Hepatitis Roundtable estimates. HCV-related kidney disease, depression, skin disorders, lymphoma and other conditions can seriously impact a patient, even wi...

Population-based estimate of hepatitis C virus prevalence in Ontario, Canada

To date, national prevalence estimates for HCV in Canada are based largely on modeling studies, which relied on limited and often poor quality, non-population level data, making it very difficult to develop appropriate policy recommendations. The aim of this study was to perform a serosurvey to obtain a population-based estimate of the prevalence of HCV infection in Ontario by birth cohort, allowing for an estimate of the number of HCV cases by age cohort

The Week in Review: January 5 – January 12, 2018

Friday, January 12, 2018 News Recap: Officials warn customers of London, Ont., nail salon to get tested for HIV, hepatitis B, C. The Middlesex-London Health Unit issued an alert warning clients of Cali Nails in the White Oaks Mall that they should talk to their doctors. A customer who contracted hepatitis B went to the salon for a manicure and pedicure. The advisory is for anyone who visited the salon between May 4, 2017, and Jan. 5, 2018. Dynavax...